ArticlePeerJ. Computer science2023
GeneCompete: an integrative tool of a novel union algorithm with various ranking techniques for multiple gene expression data.
Article in PeerJ. Computer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HuNT: A Reference Transcriptome Atlas for Human Normal Tissues.Phenomics (Cham, Switzerland) · 2026Article
- Array comparative genomic hybridisation in haematological malignancies: A comprehensive review.African journal of laboratory medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identifying the genes responsible for diseases requires precise prioritization of significant genes. Gene expression analysis enables differentiation between gene expressions in disease and normal samples. Increasing the number of high-quality samples enhances the strength of evidence regarding gene involvement in diseases. This process has led to the discovery of disease biomarkers through the collection of diverse gene expression data. Methods: This study presents GeneCompete, a web-based tool that integrates gene expression data from multiple platforms and experiments to identify the most promising biomarkers. GeneCompete incorporates a novel union strategy and eight well-established ranking methods, including Win-Loss, Massey, Colley, Keener, Elo, Markov, PageRank, and Bi-directional PageRank algorithms, to prioritize genes across multiple gene expression datasets. Each gene in the competition is assigned a score based on log-fold change values, and significant genes are determined as winners. Results: We tested the tool on the expression datasets of Hypertrophic cardiomyopathy (HCM) and the datasets from Microarray Quality Control (MAQC) project, which include both microarray and RNA-Sequencing techniques. The results demonstrate that all ranking scores have more power to predict new occurrence datasets than the classical method. Moreover, the PageRank method with a union strategy delivers the best performance for both up-regulated and down-regulated genes. Furthermore, the top-ranking genes exhibit a strong association with the disease. For MAQC, the two-sides ranking score shows a high relationship with TaqMan validation set in all log-fold change thresholds. Conclusion: GeneCompete is a powerful web-based tool that revolutionizes the identification of disease-causing genes through the integration of gene expression data from multiple platforms and experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.